Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1,-2, and-3 and co-receptors neuropilin-1 and-2 does not predict bevacizumab response in human astrocytomas

作者：Baumgarten Peter; Blank Anna Eva; Franz Kea; Hattingen Elke; Dunst Maika; Zeiner Pia; Hoffmann Katharina; Baehr Oliver; Maeder Lisa; Goeppert Benjamin; Machein Marcia; Seifert Volker; Steinbach Joachim P; Plate Karl H; Harter Patrick N; Mittelbronn Michel^*

来源：Neuro-Oncology, 2016, 18(2): 173-183.

DOI：10.1093/neuonc/nov288

• antiangiogenic therapy
• bevacizumab
• glioma
• VEGF
• VEGF receptors

A major hallmark of malignant progression in human astrocytomas is the formation of new blood vessels. Antiangiogenic therapy using the anti-vascular endothelial growth factor (VEGF)-antibody bevacizumab leads to increased progression-free survival in glioblastoma patients but does not influence their overall survival. To date, it is unclear why antiangiogenic therapy fails in many glioblastoma patients, while a small subpopulation profits considerably from this treatment.
The aim of our study was to determine the expression of VEGF-A and its (co-) receptors by immunohistochemistry and to test the association with patient survival in 350 glioma patients. Additionally, VEGF-A expression was analyzed by in-situ hybridization. In 18 patients, the protein expression was compared with the bevacizumab response according to extended and modified RANO criteria.
We found a heterogeneous expression pattern of VEGF and its receptors in glioblastoma patients with significantly lower levels in WHO grade II and III tumors and normal-appearing brain tissue (P < .001). Pilocytic astrocytomas (WHO grade I) showed significantly higher VEGFR-1, -2 and neuropilin-1 levels as compared to WHO grade II and III astrocytomas (P < .01) but at lower levels than glioblastomas. The expression of neuropilin-2 was low in all tumors. There was neither a significant correlation between protein expression and patient survival nor between protein levels and bevacizumab response after modified RANO criteria.
Since our data indicate that beneficial response to bevacizumab treatment is independent of the expression of VEGF-A and its (co-) receptors, further investigation is needed to decipher the underlying mechanisms of antiangiogenic treatment response.

• 出版日期2016-2